Edwards Lifesciences Corporation
EW
Peringkat dalam Saham
#482
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Harga Saham
$87.29
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$50.31B
Perubahan (1 hari)
0.96%
Perubahan (1 tahun)
15.94%
Negara
US
Perdagangan Edwards Lifesciences Corporation (EW)
Kategori
Healthcare
Rasio P/E untuk Edwards Lifesciences Corporation (EW)
Rasio P/E per October 2026 TTM: 49.68
Menurut laporan keuangan dan harga saham terbaru dari Edwards Lifesciences Corporation, rasio P/E saat ini (TTM) adalah 49.68. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 10.60.
Riwayat rasio P/E untuk Edwards Lifesciences Corporation dari 2000 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 49.68 | 6.99% |
| 2025 | 46.44 | 338.15% |
| 2024 | 10.60 | -67.87% |
| 2023 | 32.99 | 8.70% |
| 2022 | 30.35 | -43.51% |
| 2021 | 53.72 | -22.12% |
| 2020 | 68.98 | 48.61% |
| 2019 | 46.42 | 4.62% |
| 2018 | 44.37 | 16.12% |
| 2017 | 38.21 | 9.03% |
| 2016 | 35.04 | 1.90% |
| 2015 | 34.39 | 105.62% |
| 2014 | 16.73 | -10.81% |
| 2013 | 18.75 | -46.93% |
| 2012 | 35.34 | 3.23% |
| 2011 | 34.23 | -18.82% |
| 2010 | 42.16 | 97.55% |
| 2009 | 21.34 | -10.28% |
| 2008 | 23.79 | 2.00% |
| 2007 | 23.32 | 10.59% |
| 2006 | 21.09 | -32.57% |
| 2005 | 31.27 | -97.84% |
| 2004 | 1.45K | 6,328.22% |
| 2003 | 22.50 | -16.59% |
| 2002 | 26.98 | -119.89% |
| 2001 | -135.62 | 3,477.63% |
| 2000 | -3.79 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 33.11 | -33.36% |
US
|
|
| 21.39 | -56.95% |
IE
|
|
| 28.94 | -41.74% |
US
|
|
| 17.34 | -65.10% |
US
|
|
| - | - |
DE
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.